proglumide
Sign in to saveAlso known as W-5219
Proglumide, sold under the brand name Milid, is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application.
Research
954 papers- Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.International journal of molecular sciences · 2022
- Isobolographic Analyses of Proglumide-Celecoxib Interaction in Rats with Painful Diabetic Neuropathy.Drug development research · 2017
- Proglumide, a cholecystokinin antagonist, increases gastric emptying in rats.The American journal of physiology · 1987
- Proglumide analogues: potent cholecystokinin receptor antagonists.The American journal of physiology · 1985
- Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.International journal of molecular sciences · 2023
via PubMed
Wikidata facts
- Mass
- 334.189257
Show 3 more facts
- chemical formula
- C₁₈H₂₆N₂O₄
- canonical SMILES
- CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1
- Commons category
- Proglumide
via Wikidata · CC0
~2 min read
Article
2 sectionsContents
- See also
- References
Proglumide, sold under the brand name Milid, is a drug that inhibits gastrointestinal motility and reduces gastric secretions. It acts as a cholecystokinin antagonist, which blocks both the CCKA and CCKB subtypes. It was used mainly in the treatment of stomach ulcers, although it has now been largely replaced by newer drugs for this application.
An interesting side effect of proglumide is that it enhances the analgesia produced by opioid drugs, and can prevent or even reverse the development of tolerance to opioid drugs. This can make it a useful adjuvant treatment to use alongside opioid drugs in the treatment of chronic pain conditions such as cancer, where opioid analgesics may be required for long periods and development of tolerance reduces clinical efficacy of these drugs.